Avalglucosidase AlfaNCIt concept

https://www.has-sante.fr/jcms/p_3554673/fr/nexviadyme-avalglucosidase-alfa-maladie-de-pompe
2024
false
false
false
France
treatment outcome
insurance, health, reimbursement
Avalglucosidase Alfa
avalglucosidase alfa
enzyme replacement therapy
guidelines for drug use
evaluation of the transparency committee
glycogen storage disease type ii

---
https://ansm.sante.fr/tableau-acces-derogatoire/nexviadyme-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2023
false
false
false
France
French
summary of product characteristics
package leaflet
infusions, intravenous
Avalglucosidase Alfa
glycogen storage disease type ii
guidelines for drug use

---
https://ansm.sante.fr/tableau-marr/avalglucosidase-alfa
2023
false
false
false
France
French
guidelines for drug use
risk management
Infusion-Related Reaction
medication errors
Avalglucosidase Alfa
infusions, intravenous
home infusion therapy
continuity of patient care
enzyme replacement therapy
GAA protein, human
avalglucosidase alfa
monitoring, immunologic
glycogen storage disease type ii

---
https://www.has-sante.fr/jcms/p_3467298/fr/nexviadyme-avalglucosidase-alfa-maladie-de-pompe
2023
false
false
false
France
enzyme replacement therapy
treatment outcome
insurance, health, reimbursement
avalglucosidase alfa
adult
adolescent
child
guidelines for drug use
infusions, intravenous
evaluation of the transparency committee
glycogen storage disease type ii
Avalglucosidase Alfa

---
https://www.has-sante.fr/jcms/p_3374079/fr/nexviadyme-avalglucosidase-alfa-maladie-de-pompe
2022
false
false
false
France
guidelines for drug use
treatment outcome
insurance, health, reimbursement
infusions, intravenous
glycogen storage disease type ii
avalglucosidase alfa
Avalglucosidase Alfa
adult
child
adolescent
enzyme replacement therapy
evaluation of the transparency committee

---
https://www.ema.europa.eu/en/medicines/human/EPAR/nexviadyme
2022
false
false
false
Netherlands
French
drug approval
europe
avalglucosidase alfa
Avalglucosidase Alfa
Avalglucosidase Alfa
orphan drug production
glycogen storage disease type ii
drug evaluation
summary of product characteristics
syndication feed
package leaflet
enzyme replacement therapy
alpha-Glucosidases
infusions, intravenous
risk management
product surveillance, postmarketing
recombinant proteins
aged
pregnancy
drug evaluation, preclinical

---
https://ansm.sante.fr/tableau-atu-rtu/nexviadyme-100-mg-poudre-pour-solution-a-diluer-pour-perfusion
2021
false
false
false
France
French
summary of product characteristics
package leaflet
Avalglucosidase Alfa
Avalglucosidase Alfa
adult
child
glycogen storage disease type ii
infusions, intravenous
alpha-Glucosidases
alpha-Glucosidases
dna, recombinant
GAA protein, human
GAA protein, human

---